JNJ Johnson & Johnson JNJ · NYSE · Healthcare
SEC EDGAR ↗ SEC EDGAR Filings checked 23 Oct 2026, 16:23 UTC Financials checked 23 Oct 2026, 16:23 UTC
Some records were last checked more than 24 hours ago. These are the last verified records; check the official source for the latest filings.
Annual reporting period: 2024-12-30 — 2025-12-28 · USD
Annual revenue $94.19B Year over year +6.0%
Annual net income $26.8B Consolidated net income
Annual operating income — Standard fact unavailable
Operating margin — Operating income / revenue
Revenue over time ANNUAL
2017-01-01 · 71,890,000,000 USD
2017 $71.89B
2017-12-31 · 76,450,000,000 USD
2017 $76.45B
2018-12-30 · 81,581,000,000 USD
2018 $81.58B
2019-12-29 · 82,059,000,000 USD
2019 $82.06B
2021-01-03 · 82,584,000,000 USD
2021 $82.58B
2022-01-02 · 78,740,000,000 USD
2022 $78.74B
2023-01-01 · 79,990,000,000 USD
2023 $79.99B
2023-12-31 · 85,159,000,000 USD
2023 $85.16B
2024-12-29 · 88,821,000,000 USD
2024 $88.82B
2025-12-28 · 94,193,000,000 USD
2025 $94.19B Each bar is one fiscal year of revenue, ending on the date shown.
Income statement CONSOLIDATED Line 2025 12-28 2024 2023 2023 01-01 2022 01-02 2021 01-03 2019 12-29 2018 2017 2017 01-01 Revenue $94.19B $88.82B $85.16B $79.99B $78.74B $82.58B $82.06B $81.58B $76.45B $71.89B Cost of revenue $30.26B $27.47B $26.55B $24.6B $23.4B $28.43B $27.56B $27.09B $25.44B — Gross profit $63.94B $61.35B $58.61B $55.39B $55.34B $54.16B $54.5B $54.49B $51.01B $50.1B Research and development $109M $1.84B $483M $0M $0M — — — — — Selling, general and administrative $23.68B $22.87B $21.51B $20.25B $20.12B $22.08B $22.18B $22.54B $21.52B $20.07B Income tax expense $5.78B $2.62B $1.74B $2.99B $1.38B $1.78B $2.21B $2.7B $16.37B $3.26B Net income $26.8B $14.07B $35.15B $17.94B $20.88B $14.71B $15.12B $15.3B $1.3B $16.54B Basic EPS 11.13 5.84 13.88 6.83 7.93 5.59 5.72 5.70 0.48 6.04 Diluted EPS 11.03 5.79 13.72 6.73 7.81 5.51 5.63 5.61 0.47 5.93 Diluted shares outstanding 2.43B 2.43B 2.56B 2.66B 2.67B 2.67B 2.68B 2.73B 2.75B 2.79B
Balance sheet CONSOLIDATED Line 2025 12-28 2024 2023 2023 01-01 2022 01-02 2021 01-03 2019 12-29 2018 2017 2017 01-01 Total assets $199.21B $180.1B $167.56B $187.38B $182.02B $174.89B $157.73B $152.95B $157.3B $141.21B Current assets $55.62B $55.89B $53.5B $55.29B $60.98B $51.24B $45.27B $46.03B $43.09B $65.03B Cash and equivalents $19.71B $24.11B $21.86B $12.89B $14.49B $13.99B $17.31B $18.11B $17.82B $18.97B Short-term investments $393M $417M $1.07B $9.39B $17.12B $11.2B $1.98B $1.58B $472M $22.94B Accounts receivable $17.18B $14.84B $14.87B $14.04B $15.28B $13.58B $14.48B $14.1B $13.49B $11.7B Inventory $14.19B $12.44B $11.18B $10.27B $10.39B $9.34B $9.02B $8.6B $8.77B $8.14B Property, plant and equipment $23.17B $20.52B $19.9B $17.98B $18.96B $18.77B $17.66B $17.04B $17.01B $15.91B Total liabilities $117.67B $108.61B $98.78B $110.57B $108B $111.62B $98.26B $93.2B $97.14B $70.79B Current liabilities $54.13B $50.32B $46.28B $55.8B $45.23B $42.49B $35.96B $31.23B $30.54B $26.29B Accounts payable $11.99B $10.31B $9.63B $9.89B $11.06B $9.51B $8.54B $7.54B $7.31B $6.92B Short-term debt $2B $1.75B $1.47B $1.55B $2.13B $1.8B $1.2B $2.6B $1.5B $1.7B Long-term debt $39.44B $30.65B $25.88B $26.89B $29.99B $32.64B $26.49B $27.68B $30.68B $22.44B Shareholders' equity $81.54B $71.49B $68.77B $76.8B $74.02B $63.28B $59.47B $59.75B $60.16B $70.42B Retained earnings $168.98B $155.79B $153.84B $128.35B $123.06B $113.89B $110.66B $106.22B $101.79B $110.55B
Cash flow statement CONSOLIDATED Line 2025 12-28 2024 2023 2023 01-01 2022 01-02 2021 01-03 2019 12-29 2018 2017 2017 01-01 Operating cash flow $24.53B $24.27B $22.79B $21.19B $23.41B $23.54B $23.42B $22.2B $21.06B $18.77B Investing cash flow $-23.59B $-18.6B $878M $-12.37B $-8.68B $-20.83B $-6.19B $-3.17B $-14.87B $-4.76B Financing cash flow $-5.54B $-3.13B $-15.83B $-8.87B $-14.05B $-6.12B $-18.02B $-18.51B $-7.67B $-8.55B Capital expenditure $4.83B $4.42B $4.54B $4.01B $3.65B $3.35B $3.5B $3.67B $3.28B $3.23B Depreciation and amortisation $7.5B $7.34B $7.49B $6.97B $7.39B $7.23B $7.01B $6.93B $5.64B $3.75B Dividends paid $12.38B $11.82B $11.77B $11.68B $11.03B $10.48B $9.92B $9.49B $8.94B $8.62B Share buybacks $5.95B $2.43B $5.05B $6.04B $3.46B $3.22B $6.75B $5.87B $6.36B $8.98B
Key ratios COMPUTED HERE Line 2025 12-28 2024 2023 2023 01-01 2022 01-02 2021 01-03 2019 12-29 2018 2017 2017 01-01 Gross margin 67.9% 69.1% 68.8% 69.3% 70.3% 65.6% 66.4% 66.8% 66.7% — Net margin 28.5% 15.8% 41.3% 22.4% 26.5% 17.8% 18.4% 18.8% 1.7% 23.0% Return on equity 32.9% 19.7% 51.1% 23.4% 28.2% 23.3% 25.4% 25.6% 2.2% 23.5% Return on assets 13.5% 7.8% 21.0% 9.6% 11.5% 8.4% 9.6% 10.0% 0.8% 11.7% Asset turnover 0.47× 0.49× 0.51× 0.43× 0.43× 0.47× 0.52× 0.53× 0.49× 0.51× Current ratio 1.03× 1.11× 1.16× 0.99× 1.35× 1.21× 1.26× 1.47× 1.41× 2.47× Debt to equity 144.3% 151.9% 143.6% 144.0% 145.9% 176.4% 165.2% 156.0% 161.5% 100.5% Net debt $21.73B $8.3B $5.49B $15.55B $17.63B $20.45B $10.39B $12.18B $14.35B $5.17B Free cash flow $19.7B $19.84B $18.25B $17.19B $19.76B $20.19B $19.92B $18.53B $17.78B $15.54B Cash conversion cycle 93d 89d 85d 70d 60d 58d 71d 77d 85d —
Amounts are as filed. An em dash means that line was not reported, not that it is nil; rows marked “computed” and the whole key-ratios table are worked out here from those amounts.
About this record 10 fiscal years from 2017 to 2025, covering 31 statement lines, collected from SEC EDGAR. The most recent was confirmed on 2026-02-11.
The fiscal year does not follow the calendar: the most recent one ran from 2024-12-30 to 2025-12-28. Set beside a December-year company it would be two different twelve-month periods compared as one.
This page offers no investment view or forecast about Johnson & Johnson. The amounts are as the company filed them, the ratios follow from those amounts, and no currency is converted.
Run these figures through the calculators · Reading guides · Methodology